WVE · Wave Life Sciences Ltd.

Wave Life Sciences Ltd. reported financial results for the first quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1, highlighting a strong balance sheet with $544.6 million in cash and cash equivalents, extending the runway into the third quarter of 2028. This positions the company to fund ongoing and planned clinical trials without near-term financing needs. CEO Paul Bolno emphasized acceleration of WVE-007, an investigational GalNAc-siRNA targeting INHBE for obesity, following positive Phase 1 INLIGHT results showing -5.3% total body fat reduction, -14.3% visceral fat reduction (p<0.001), and +2.4% muscle preservation at six months post-single 240 mg dose, with favorable safety. The FDA has accepted the Phase 2a multidose portion in higher BMI (35-50 kg/m²) individuals with and without type 2 diabetes, set to initiate in Q2 2026, assessing cardiometabolic biomarkers for potential in obesity, MASH, T2D, and CVD. Combination and maintenance trials for WVE-007 are also planned for 2026. In RNA editing, RestorAATion-2 trial data for WVE-006 in AATD, including higher doses, will be presented at the ATS International Conference in May 2026, with regulatory feedback on accelerated approval expected mid-year. WVE-008 CTA for PNPLA3 liver disease remains on track for 2026. An updated corporate presentation (Exhibit 99.2) details the pipeline, underscoring WVE-007's differentiated mechanism of targeted lipolysis preserving muscle, supported by human genetics and preclinical data showing durable fat loss and synergy with GLP-1s.